SARS-CoV Inhibitor

GC813 is a MERS-CoV 3CL protease (3CL_pro) and MERS-CoV main protease (M_pro) inhibitor. GC813 can be used for the research of middle east respiratory syndrome.

Verbenalin (Standard) is the analytical standard of Verbenalin. This product is intended for research and analytical applications. Verbenalin is an orally active terpenoid glycoside that can be extracted from the medicinal plant Verbena officinalis. Verbenalin has anti-inflammatory, antiviral, and neuroprotective effects. Verbenalin has a strong binding affinity to the nsp-12 protein of the SARS-CoV-2 virus. Verbenalin can be used in the research of inflammatory and nervous system diseases such as hepatitis and Alzheimer's disease.

SARS-CoV-2-IN-67 (Compound 16), a vitamin K derivatives, has anti-SARS-CoV-2 activity (EC₅₀: 64.8 μM in VeroE6/TMPRSS2 cells). SARS-CoV-2-IN-67 inhibits SARS-CoV-2 RdRp activity.

Chloroquine (dihydrochloride) (Standard) is the analytical standard of Chloroquine (dihydrochloride). This product is intended for research and analytical applications. Chloroquine dihydrochloride is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine dihydrochloride is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine dihydrochloride is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

ONO-5334 (Standard) is the analytical standard of ONO-5334 (HY-108044). This product is intended for research and analytical applications. ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with K_i values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC₅₀ value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease.

SARS-CoV-2 Mpro-IN-37 (compound 8r) is a SARS-CoV-2 main protease (M^pro) inhibitor, with an IC₅₀ of 0.0199 μM. SARS-CoV-2 Mpro-IN-37 inhibits SARS-CoV-1 M^pro and MERS-CoV M^pro with IC₅₀s of 0.00945 and 0.111 μM, respectively. SARS-CoV-2 Mpro-IN-37 displays high antiviral activity in the nanomolar range without showing cellular toxicity.

SARS-CoV-2 Mpro-IN-47 is an orally active SARS-CoV-2 Mpro reversible covalent Inhibitor. SARS-CoV-2 Mpro-IN-47 shows potent antiviral activity against several clinical variants of SARS-CoV-2. SARS-CoV-2 Mpro-IN-47 can be used for the research of infection, such as SARS-CoV-2.

Jobosic acid, a saturated fatty acid, is a selective SARS-CoV-2 inhibitor. Jobosic acid inhibits Mpro and spike-RBD/ACE-2 interaction with IC₅₀ values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid shows viral entry inhibition for the omicron SARS-CoV-2 variant.

PI3Kδ-IN-27 is an PI3Kδ inhibitor with an IC₅₀ of 355.3 nM. PI3Kδ-IN-27 exhibits anti-SARS-CoV-2 activity. PI3Kδ-IN-27 can be used for the research of infection, such as COVID-19.

SARS-CoV-2-IN-69 (Compound 7E) is a non-covalent SARS-CoV-2 inhibitor with an EC₅₀ value of 7.4 μM. SARS-CoV-2-IN-69 is a potent inhibitor of SARS-CoV-2 main protease (M^pro) and a non-covalent inhibitor of papain (PL^pro).

SARS-CoV-2-IN-70 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC₅₀ of 3.2 μM.

UAWJ9-36-3 is a M^pro and cathepsin L (IC₅₀: 1.81 μM) inhibitor. UAWJ9-36-3 shows potent binding and enzymatic inhibition against the M^pros from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1. UAWJ9-36-3 demonstrates broad-spectrum antiviral activity against not only SARS-CoV-2, but also the common human coronaviruses HCoV-OC43, HCoV-NL63, and HCoV-229E.

SARS-CoV-2 Mpro-IN-55 is a SARS-CoV-2 M^pro inhibitor with a IC₅₀ value of 7.20 nM. SARS-CoV-2 Mpro-IN-55 shows limited inhibitory activity against SARS-CoV-2. SARS-CoV-2 Mpro-IN-55 can be used in research related to COVID-19.

Baimaside (Standard) is the analytical standard of Baimaside. This product is intended for research and analytical applications. Baimaside (Quercetin 3-O-sophoroside) is a flavonoid cholinergic function modulator that binds to SARS-CoV-2-related targets. Baimaside regulates the expression of cholinergic system-related proteins and acetylcholine levels, improves scopolamine-induced learning and memory impairment, protects hippocampal neurons, inhibits pollen protein fluorescence, and protects pollen DNA. Its biosynthesis is regulated by multiple enzymes. Baimaside is completely absorbed in rats, undergoes phase Ⅱ metabolism and gut microbiota decomposition, and inhibits the invasion and proliferation of SARS-CoV-2 and its variants, making it suitable for research related to Alzheimer's disease and COVID-19.

Azelastine (hydrochloride) (Standard) is the analytical standard of Azelastine (hydrochloride). This product is intended for research and analytical applications. Azelastine hydrochloridem, an antihistamine, is a potent and selective histamine 1 (H₁) antagonist. Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.

SARS-CoV-2-IN-77 (compound 11e) is a cathepsin L and cathepsin S inhibitor with K_i values of 111 nM and 103 nM, respectively. SARS-CoV-2-IN-77 inhibits SARS-CoV-2 with an EC₅₀ value of 38.4 nM in Calu-3 cells without showing cytotoxicity.

MI-23 is a SARS-CoV-2 main protease (SARS-CoV-2 M_pro) inhibitor with an IC₅₀ of 7.6 nM. MI-23 is applicable to the research of COVID-19.

Molnupiravir (Standard) is the analytical standard of Molnupiravir. This product is intended for research and analytical applications. Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza.

F594-1001 (compound 6) hydrochloride is a potent and highly selective SARS-CoV-2 Mac1-ADP-ribose inhibitor with IC₅₀s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 hydrochloride directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity.

SARS-CoV-2-IN-119 (Compound A28) is a SARS-CoV-2 fusion inhibitor. SARS-CoV-2-IN-119 strongly inhibits Omicron entry with an EC₅₀s of 1.95  and 1.08 μM for pOmicron (BA.2.86.1) and wild Omicron. SARS-CoV-2-IN-119 also has antiviral activities against wild SARS-CoV-2 and other variants, such as pseudotyped Delta SARS-CoV-2, pOmicron (BA.4) and (KP.3). SARS-CoV-2-IN-119 directly interferes with Omicron S2-mediated viral membrane fusion to block Omicron virus into host cells. SARS-CoV-2-IN-119 can be used for COVID-19 research.